1
|
Bendi A, Yadav P, Saini K, Singh Bhathiwal A, Raghav N. A Comprehensive Examination of Heterocyclic Scaffold Chemistry for Antitubercular Activity. Chem Biodivers 2024; 21:e202400067. [PMID: 38500408 DOI: 10.1002/cbdv.202400067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2024] [Revised: 03/18/2024] [Accepted: 03/18/2024] [Indexed: 03/20/2024]
Abstract
Tuberculosis is a communicable disease which affects humans particularly the lungs and is transmitted mainly through air. Despite two decades of intensive research aimed at understanding and combating tuberculosis, persistent biological uncertainties continue to hinder progress. Nowadays, heterocyclic compounds have proven themselves in effective treatment of tuberculosis because of their wide range of biological and pharmacological activities. Antituberculosis or antimycobacterial agents encompass a broad array of compounds utilized singly or in conjunction to combat Mycobacterium infections, spanning from tuberculosis to leprosy. Here, we summarize the synthesis of various heterocyclic compounds which includes the greener synthetic route as well as use of nano compounds as catalyst along with their anti TB activities.
Collapse
Affiliation(s)
- Anjaneyulu Bendi
- Department of Chemistry, Presidency University, Rajanukunte, Itgalpura, 560064, Bangalore, India
| | - Priyanka Yadav
- Department of Chemistry, Faculty of Science, SGT University, 122505, Gurugram, Haryana, India
| | - Komal Saini
- Applied Sciences and Humanities, World College of Technology and Management, 122506, Gurugram, Haryana, India
| | - Anirudh Singh Bhathiwal
- Department of Chemistry, Faculty of Science, SGT University, 122505, Gurugram, Haryana, India
| | - Neera Raghav
- Department of Chemistry, Kurukshetra University, 136119, Kurukshetra, Haryana, India
| |
Collapse
|
2
|
Kushwaha N, Sahu A, Mishra J, Soni A, Dorwal D. An Insight on the Prospect of Quinazoline and Quinazolinone Derivatives as Anti-tubercular Agents. Curr Org Synth 2023; 20:838-869. [PMID: 36927421 DOI: 10.2174/1570179420666230316094435] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2022] [Revised: 01/22/2023] [Accepted: 01/27/2023] [Indexed: 03/18/2023]
Abstract
Multiple potential drugs have been developed based on the heterocyclic molecules for the treatment of different symptoms. Among the existing heterocyclic molecules, quinazoline and quinazolinone derivatives have been found to exhibit extensive pharmacological and biological characteristics. One significant property of these molecules is their potency as anti-tubercular agents. Thus, both quinazoline and quinazolinone derivatives are modified using different functional groups as substituents for investigating their anti-tubercular activities. We present a summary of the reported anti-tubercular drugs, designed using quinazoline and quinazolinone derivatives, in this review.
Collapse
Affiliation(s)
| | - Adarsh Sahu
- Department of Pharmaceutical Sciences, Harisingh Gour Vishwavidyalaya, Sagar, MP, India
| | - Jyotika Mishra
- Department of Pharmaceutical Sciences, Harisingh Gour Vishwavidyalaya, Sagar, MP, India
| | - Ankit Soni
- Sri Aurobindo Institute of Pharmacy, Indore, MP, India
| | - Dhawal Dorwal
- Sri Aurobindo Institute of Pharmacy, Indore, MP, India
| |
Collapse
|
3
|
Dutta A, Trivedi P, Gehlot PS, Gogoi D, Hazarika R, Chetia P, Kumar A, Chaliha AK, Chaturvedi V, Sarma D. Design and Synthesis of Quinazolinone-Triazole Hybrids as Potent Anti-Tubercular Agents. ACS APPLIED BIO MATERIALS 2022; 5:4413-4424. [PMID: 36053225 DOI: 10.1021/acsabm.2c00562] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
A straightforward and convenient methodology has been developed for the reaction of 2-aminobenzamide and carbonyls affording 2,3-dihydroquinazolin-4(1H)-ones using aqueous solution of [C12Py][FeCl3Br]. The developed methodology was applied for the synthesis of 25 quinazolinone-triazole hybrids followed by evaluation of their in vitro anti-tubercular (TB) activity. The results revealed that 8 quinazolinone-triazole hybrids displayed promising activity having MIC values of 0.78-12.5 μg/mL. The compound 3if with MIC 0.78 μg/mL was found to be the lead nominee among the series, better than Ethambutol, a first line anti-TB drug and comparable with Rifampicin. The active compounds with MIC values ≤ 6.25 μg/mL were subjected to in vitro cytotoxicity and found nontoxic. In drug-drug interaction, compounds 3ia and 3ii interacted synergistically with all the three anti-TB drugs, INH, RFM, and EMB. Other 3 compounds interacted either in synergistic or additive manners. Important information on the binding interaction of the target compounds with the active sites of 1DQY Antigen 85C from Mycobacterium tuberculosis and Enoyl acyl carrier protein reductase (InhA) enzymes was obtained from molecular docking studies. Screening of the drug-likeness properties and bioactivity score indicates that synthesized molecules could be projected as potential drug candidates. Based on the current study, quinazolinone-triazole hybrids framework can be useful in drug development for TB.
Collapse
Affiliation(s)
- Apurba Dutta
- Department of Chemistry, Dibrugarh University, Dibrugarh, Assam 786004, India
| | - Priyanka Trivedi
- Biochemistry Division, Central Drug Research Institute, CSIR, Lucknow 226001, India
| | - Praveen Singh Gehlot
- AcSIR, Salt and Marine Chemicals Division, CSIR-Central Salt and Marine Chemicals Research Institute, Bhavnagar 364002, India
| | - Dipshikha Gogoi
- Centre for Biotechnology and Bioinformatics, Dibrugarh University, Dibrugarh, Assam 786004, India
| | - Roktopol Hazarika
- Department of Chemistry, Dibrugarh University, Dibrugarh, Assam 786004, India
| | - Pankaj Chetia
- Department of Life Sciences, Dibrugarh University, Dibrugarh, Assam 786004, India
| | - Arvind Kumar
- AcSIR, Salt and Marine Chemicals Division, CSIR-Central Salt and Marine Chemicals Research Institute, Bhavnagar 364002, India
| | - Amrita Kashyap Chaliha
- Centre for Biotechnology and Bioinformatics, Dibrugarh University, Dibrugarh, Assam 786004, India
| | - Vinita Chaturvedi
- Biochemistry Division, Central Drug Research Institute, CSIR, Lucknow 226001, India
| | - Diganta Sarma
- Department of Chemistry, Dibrugarh University, Dibrugarh, Assam 786004, India
| |
Collapse
|
4
|
Pérez-Fehrmann M, Kesternich V, Puelles A, Quezada V, Salazar F, Christen P, Castillo J, Cárcamo JG, Castro-Alvarez A, Nelson R. Synthesis, antitumor activity, 3D-QSAR and molecular docking studies of new iodinated 4-(3 H)-quinazolinones 3 N-substituted. RSC Adv 2022; 12:21340-21352. [PMID: 35975048 PMCID: PMC9344282 DOI: 10.1039/d2ra03684c] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2022] [Accepted: 07/19/2022] [Indexed: 01/09/2023] Open
Abstract
A novel series of 6-iodo-2-methylquinazolin-4-(3H)-one derivatives, 3a–n, were synthesized and evaluated for their in vitro cytotoxic activity. Compounds 3a, 3b, 3d, 3e, and 3h showed remarkable cytotoxic activity on specific human cancer cell lines when compared to the anti-cancer drug, paclitaxel. Compound 3a was found to be particularly effective on promyelocytic leukaemia HL60 and non-Hodgkin lymphoma U937, with IC50 values of 21 and 30 μM, respectively. Compound 3d showed significant activity against cervical cancer HeLa (IC50 = 10 μM). The compounds 3e and 3h were strongly active against glioblastoma multiform tumour T98G, with IC50 values of 12 and 22 μM, respectively. These five compounds showed an interesting cytotoxic activity on four human cancer cell types of high incidence. The molecular docking results reveal a good correlation between experimental activity and calculated binding affinity on dihydrofolate reductase (DHFR). Docking studies proved 3d as the most potent compound. In addition, the three-dimensional quantitative structure–activity relationship (3D-QSAR) analysis exhibited activities that may indicate the existence of electron-withdrawing and lipophilic groups at the para-position of the phenyl ring and hydrophobic interactions of the quinazolinic ring in the DHFR active site. New iodinated 4-(3H)-quinazolinones 3N-substituted with antitumor activity and 3D-QSAR and molecular docking studies as dihydrofolate reductase (DHFR) inhibitors.![]()
Collapse
Affiliation(s)
- Marcia Pérez-Fehrmann
- Departamento de Química, Facultad de Ciencias, Universidad Católica del Norte Av. Angamos 0610 Antofagasta 1270709 Chile
| | - Víctor Kesternich
- Departamento de Química, Facultad de Ciencias, Universidad Católica del Norte Av. Angamos 0610 Antofagasta 1270709 Chile
| | - Arturo Puelles
- Departamento de Química, Facultad de Ciencias, Universidad Católica del Norte Av. Angamos 0610 Antofagasta 1270709 Chile
| | - Víctor Quezada
- Departamento de Química, Facultad de Ciencias, Universidad Católica del Norte Av. Angamos 0610 Antofagasta 1270709 Chile
| | - Fernanda Salazar
- Departamento de Química, Facultad de Ciencias, Universidad Católica del Norte Av. Angamos 0610 Antofagasta 1270709 Chile
| | - Philippe Christen
- School of Pharmaceutical Sciences University of Geneva 1211 Geneva 4 Switzerland.,Institute of Pharmaceutical Sciences of Western Switzerland University of Geneva 1211 Geneva 4 Switzerland
| | - Jonathan Castillo
- Instituto de Bioquímica y Microbiología, Facultad de Ciencias, Universidad Austral de Chile Campus Isla Teja Valdivia Chile
| | - Juan Guillermo Cárcamo
- Instituto de Bioquímica y Microbiología, Facultad de Ciencias, Universidad Austral de Chile Campus Isla Teja Valdivia Chile.,Centro FONDAP, Interdisciplinary Center for Aquaculture Research (INCAR) Chile
| | - Alejandro Castro-Alvarez
- Laboratorio de Bioproductos Farmacéuticos y Cosméticos, Centro de Excelencia en Medicina Traslacional, Facultad de Medicina, Universidad de La Frontera Av. Francisco Salazar 01145 Temuco 4780000 Chile.,Departamento de Química de los Materiales, Facultad de Química y Biología, Universidad de Santiago de Chile Casilla 40, Correo 33 Santiago Chile
| | - Ronald Nelson
- Departamento de Química, Facultad de Ciencias, Universidad Católica del Norte Av. Angamos 0610 Antofagasta 1270709 Chile
| |
Collapse
|
5
|
Dehbi O, Riadi Y, Geesi MH, Anouar EH, Ibnouf EO, Azzallou R. Synthesis, Characterization, Antibacterial Evaluation, and Molecular Docking of New Quinazolinone-Based Derivatives. Polycycl Aromat Compd 2022. [DOI: 10.1080/10406638.2022.2041053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- Oussama Dehbi
- École Supérieure en Ingénierie D'information, Télécommunication, Management et Génie Civil (ESTEM), Casablanca, Morocco
| | - Yassine Riadi
- Department of Pharmaceutical Chemistry, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia 11942
| | - Mohammed H. Geesi
- Department of Chemistry, College of Science and Humanities in Al-Kharj, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia 11942
| | - El Hassane Anouar
- Department of Chemistry, College of Science and Humanities in Al-Kharj, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia 11942
| | - Elmutasim O. Ibnouf
- Department of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia 11942
- Department of Medical Microbiology, Faculty of Medical Laboratory Sciences, Omdurman Islamic University, Sudan
| | - Rachid Azzallou
- Equipe de Matériaux, Catalyse et Valorisation Des Ressources Naturelles, Faculté Des Sciences, Université Ibn Zohr, Agadir, BP, Maroc 8106
- Laboratoire de Biochimie, Environnement & Agroalimentaire, URAC 36, Faculté Des Sciences et Techniques de Mohammedia, Université Hassan II-Casablanca, Mohammedia, Maroc
| |
Collapse
|
6
|
Recent advancements and developments in search of anti-tuberculosis agents: A quinquennial update and future directions. J Mol Struct 2022. [DOI: 10.1016/j.molstruc.2021.131473] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
7
|
Anti-TB evaluation of novel 2,3-dihydroquinazolin-4(1H)-ones and in silico studies of the active compounds. Med Chem Res 2021. [DOI: 10.1007/s00044-021-02733-6] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
|
8
|
Dutta A, Sarma D. Recent advances in the synthesis of Quinazoline analogues as Anti-TB agents. Tuberculosis (Edinb) 2020; 124:101986. [PMID: 32942187 DOI: 10.1016/j.tube.2020.101986] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2020] [Revised: 07/21/2020] [Accepted: 07/30/2020] [Indexed: 11/29/2022]
Abstract
Quinazoline analogues are one of the important nitrogen containing heterocycles that have significant bioactivity as well as found in a plethora of natural products. Tuberculosis is one of the serious universal health threats caused by Mycobacteriumtuberculosis (MTB) and primarily affects the lungs. Due to their significant bioactivity and natural occurrences of quinazolines, researchers are trying to synthesize new quinazoline analogues which may have significant potency against tuberculosis. This particular review summarizes recent development of different types of quinazoline bearing analogues as anti-tubercular (anti-TB) agents and their synthesis with structure-activity relationship.
Collapse
Affiliation(s)
- Apurba Dutta
- Department of Chemistry, Dibrugarh University, Dibrugarh, 786004, Assam, India
| | - Diganta Sarma
- Department of Chemistry, Dibrugarh University, Dibrugarh, 786004, Assam, India.
| |
Collapse
|
9
|
Akester JN, Njaria P, Nchinda A, Le Manach C, Myrick A, Singh V, Lawrence N, Njoroge M, Taylor D, Moosa A, Smith AJ, Brooks EJ, Lenaerts AJ, Robertson GT, Ioerger TR, Mueller R, Chibale K. Synthesis, Structure-Activity Relationship, and Mechanistic Studies of Aminoquinazolinones Displaying Antimycobacterial Activity. ACS Infect Dis 2020; 6:1951-1964. [PMID: 32470286 PMCID: PMC7359024 DOI: 10.1021/acsinfecdis.0c00252] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
![]()
Phenotypic whole-cell screening against Mycobacterium tuberculosis (Mtb) in glycerol–alanine–salts
supplemented with Tween 80 and iron (GASTE-Fe) media led to the identification
of a 2-aminoquinazolinone hit compound, sulfone 1 which
was optimized for solubility by replacing the sulfone moiety with
a sulfoxide 2. The synthesis and structure–activity
relationship (SAR) studies identified several compounds with potent
antimycobacterial activity, which were metabolically stable and noncytotoxic.
Compound 2 displayed favorable in vitro properties and was therefore selected for in vivo pharmacokinetic (PK) studies where it was found to be extensively
metabolized to the sulfone 1. Both derivatives exhibited
promising PK parameters; however, when 2 was evaluated
for in vivo efficacy in an acute TB infection mouse
model, it was found to be inactive. In order to understand the in vitro and in vivo discrepancy, compound 2 was subsequently retested in vitro using
different Mtb strains cultured in different media.
This revealed that activity was only observed in media containing
glycerol and led to the hypothesis that glycerol was not used as a
primary carbon source by Mtb in the mouse lungs,
as has previously been observed. Support for this hypothesis was provided
by spontaneous-resistant mutant generation and whole genome sequencing
studies, which revealed mutations mapping to glycerol metabolizing
genes indicating that the 2-aminoquinazolinones kill Mtb in
vitro via a glycerol-dependent mechanism of action.
Collapse
Affiliation(s)
- Jessica N. Akester
- Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa
| | - Paul Njaria
- Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa
| | - Aloysius Nchinda
- Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa
| | - Claire Le Manach
- Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa
| | - Alissa Myrick
- Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa
- Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Rondebosch 7701, South Africa
| | - Vinayak Singh
- Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa
- Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Rondebosch 7701, South Africa
- South African Medical Research Council Drug Discovery and Development Research Unit, Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa
| | - Nina Lawrence
- H3D, Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory 7925, South Africa
| | - Mathew Njoroge
- H3D, Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory 7925, South Africa
| | - Dale Taylor
- H3D, Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory 7925, South Africa
| | - Atica Moosa
- MRC/NHLS/UCT Molecular Mycobacteriology Research Unit, Department of Pathology, University of Cape Town, Rondebosch 7701, South Africa
| | - Anthony J. Smith
- Mycobacteria Research Laboratories, Department of Microbiology, Immunology, and Pathology, Colorado State University, 200 West Lake Street, Fort Collins, Colorado 80523, United States
| | - Elizabeth J. Brooks
- Mycobacteria Research Laboratories, Department of Microbiology, Immunology, and Pathology, Colorado State University, 200 West Lake Street, Fort Collins, Colorado 80523, United States
| | - Anne J. Lenaerts
- Mycobacteria Research Laboratories, Department of Microbiology, Immunology, and Pathology, Colorado State University, 200 West Lake Street, Fort Collins, Colorado 80523, United States
| | - Gregory T. Robertson
- Mycobacteria Research Laboratories, Department of Microbiology, Immunology, and Pathology, Colorado State University, 200 West Lake Street, Fort Collins, Colorado 80523, United States
| | - Thomas R. Ioerger
- Department of Computer Science, Texas A&M University, College Station, Texas 77843-3112, United States
| | - Rudolf Mueller
- Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa
| | - Kelly Chibale
- Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa
- Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa
- Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Rondebosch 7701, South Africa
- South African Medical Research Council Drug Discovery and Development Research Unit, Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa
| |
Collapse
|
10
|
Padmini T, Bhikshapathi D, Suresh K, Kulkarni R, Kamal BR. Novel Aminopyrazole Tagged Hydrazones as Anti-Tubercular Agents: Synthesis and Molecular Docking Studies. Med Chem 2020; 17:344-351. [PMID: 32407282 DOI: 10.2174/1573406416666200514084747] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2019] [Revised: 04/09/2020] [Accepted: 04/20/2020] [Indexed: 11/22/2022]
Abstract
BACKGROUND Pyrazole derivatives have been reported to possess numerous pharmacological activities viz., anti-inflammatory, antipsychotic, etc. Our group has disclosed that pyrazole benzamides display potent antibacterial and anti-tubercular activities. OBJECTIVE Synthesis of new pyrazole acetamides which possess hydrazone group to be evaluated for antitubercular activity. METHODS The key intermediate 5-aminopyrazole was synthesized with the known procedure, which is then converted into chloroacetamide. This compound than resulted in hydrazine derivative and finally converted into aromatic hydrazones. All the compounds were screened for antitubercular activity. RESULTS All the synthesized compounds have been characterized by their spectral data obtained and subjected to anti-tubercular activity. Among all the twenty tested compounds, three compounds, 5a5, 5b5 and 5b7 have demonstrated MIC value of 3.12 μg/mL against MTB H37Rv. Docking studies revealed important hydrogen bonding interactions with InhA. CONCLUSION Three compounds 5a5, 5b5 and 5b7 were found to be most potent among the series of compounds. Docking studies of compounds explained the presence of hydrogen bonding and π- π stacking interactions with InhA. Further synthesis of more such derivatives with optimized groups would produce compounds with more potent anti-tubercular activity.
Collapse
Affiliation(s)
| | - Darna Bhikshapathi
- Teegala Ram Reddy College of Pharmacy, Pragathi Colony, Meerpet, Hyderabad- 500097, Telangana, India
| | - Kandagatla Suresh
- Vijaya College of Pharmacy, Hayatnagar, Hyderabad-501511, Telangana, Hyderabad, India
| | - Ravindra Kulkarni
- Bharati Vidyapeeth's Poona College of Pharmacy, Erandwane, Pune-411038, Maharashtra, India
| | - Bigala R Kamal
- Research Supervisor, Mewar University, Chittorgarh, Rajasthan, India
| |
Collapse
|
11
|
Li X, Hernandez V, Rock FL, Choi W, Mak YSL, Mohan M, Mao W, Zhou Y, Easom EE, Plattner JJ, Zou W, Pérez-Herrán E, Giordano I, Mendoza-Losana A, Alemparte C, Rullas J, Angulo-Barturen I, Crouch S, Ortega F, Barros D, Alley MRK. Discovery of a Potent and Specific M. tuberculosis Leucyl-tRNA Synthetase Inhibitor: (S)-3-(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3H)-ol (GSK656). J Med Chem 2017; 60:8011-8026. [PMID: 28953378 DOI: 10.1021/acs.jmedchem.7b00631] [Citation(s) in RCA: 98] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
There is an urgent need to develop new and safer antitubercular agents that possess a novel mode of action. We synthesized and evaluated a novel series of 3-aminomethyl 4-halogen benzoxaboroles as Mycobacterium tuberculosis (Mtb) leucyl-tRNA synthetase (LeuRS) inhibitors. A number of Mtb LeuRS inhibitors were identified that demonstrated good antitubercular activity with high selectivity over human mitochondrial and cytoplasmic LeuRS. Further evaluation of these Mtb LeuRS inhibitors by in vivo pharmacokinetics (PK) and murine tuberculosis (TB) efficacy models led to the discovery of GSK3036656 (abbreviated as GSK656). This molecule shows potent inhibition of Mtb LeuRS (IC50 = 0.20 μM) and in vitro antitubercular activity (Mtb H37Rv MIC = 0.08 μM). Additionally, it is highly selective for the Mtb LeuRS enzyme with IC50 of >300 μM and 132 μM for human mitochondrial LeuRS and human cytoplasmic LeuRS, respectively. In addition, it exhibits remarkable PK profiles and efficacy against Mtb in mouse TB infection models with superior tolerability over initial leads. This compound has been progressed to clinical development for the treatment of tuberculosis.
Collapse
Affiliation(s)
- Xianfeng Li
- Anacor Pharmaceuticals, Inc. , 1020 E. Meadow Circle, Palo Alto, California 94303, United States
| | - Vincent Hernandez
- Anacor Pharmaceuticals, Inc. , 1020 E. Meadow Circle, Palo Alto, California 94303, United States
| | - Fernando L Rock
- Anacor Pharmaceuticals, Inc. , 1020 E. Meadow Circle, Palo Alto, California 94303, United States
| | - Wai Choi
- Anacor Pharmaceuticals, Inc. , 1020 E. Meadow Circle, Palo Alto, California 94303, United States
| | - Yvonne S L Mak
- Anacor Pharmaceuticals, Inc. , 1020 E. Meadow Circle, Palo Alto, California 94303, United States
| | - Manisha Mohan
- Anacor Pharmaceuticals, Inc. , 1020 E. Meadow Circle, Palo Alto, California 94303, United States
| | - Weimin Mao
- Anacor Pharmaceuticals, Inc. , 1020 E. Meadow Circle, Palo Alto, California 94303, United States
| | - Yasheen Zhou
- Anacor Pharmaceuticals, Inc. , 1020 E. Meadow Circle, Palo Alto, California 94303, United States
| | - Eric E Easom
- Anacor Pharmaceuticals, Inc. , 1020 E. Meadow Circle, Palo Alto, California 94303, United States
| | - Jacob J Plattner
- Anacor Pharmaceuticals, Inc. , 1020 E. Meadow Circle, Palo Alto, California 94303, United States
| | - Wuxin Zou
- BioDuro LLC , Building E, No. 29, Life Science Park Road, Beijing 102206, P. R. China
| | - Esther Pérez-Herrán
- GlaxoSmithKline , Tres Cantos Medicines Development Campus, Severo Ochoa 2, Tres Cantos, Madrid 28760, Spain
| | - Ilaria Giordano
- GlaxoSmithKline , Tres Cantos Medicines Development Campus, Severo Ochoa 2, Tres Cantos, Madrid 28760, Spain
| | - Alfonso Mendoza-Losana
- GlaxoSmithKline , Tres Cantos Medicines Development Campus, Severo Ochoa 2, Tres Cantos, Madrid 28760, Spain
| | - Carlos Alemparte
- GlaxoSmithKline , Tres Cantos Medicines Development Campus, Severo Ochoa 2, Tres Cantos, Madrid 28760, Spain
| | - Joaquín Rullas
- GlaxoSmithKline , Tres Cantos Medicines Development Campus, Severo Ochoa 2, Tres Cantos, Madrid 28760, Spain
| | - Iñigo Angulo-Barturen
- GlaxoSmithKline , Tres Cantos Medicines Development Campus, Severo Ochoa 2, Tres Cantos, Madrid 28760, Spain
| | - Sabrinia Crouch
- GlaxoSmithKline , Tres Cantos Medicines Development Campus, Severo Ochoa 2, Tres Cantos, Madrid 28760, Spain
| | - Fátima Ortega
- GlaxoSmithKline , Tres Cantos Medicines Development Campus, Severo Ochoa 2, Tres Cantos, Madrid 28760, Spain
| | - David Barros
- GlaxoSmithKline , Tres Cantos Medicines Development Campus, Severo Ochoa 2, Tres Cantos, Madrid 28760, Spain
| | - M R K Alley
- Anacor Pharmaceuticals, Inc. , 1020 E. Meadow Circle, Palo Alto, California 94303, United States
| |
Collapse
|
12
|
Xu Z, Gao C, Ren QC, Song XF, Feng LS, Lv ZS. Recent advances of pyrazole-containing derivatives as anti-tubercular agents. Eur J Med Chem 2017; 139:429-440. [PMID: 28818767 DOI: 10.1016/j.ejmech.2017.07.059] [Citation(s) in RCA: 157] [Impact Index Per Article: 22.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2017] [Revised: 07/23/2017] [Accepted: 07/24/2017] [Indexed: 01/18/2023]
Abstract
One-third of the world's population infected tuberculosis (TB), and more than 1 million deaths annually. The co-infection between the mainly pathogen Mycobacterium tuberculosis (MTB) and HIV, and the incidence of drug-resistant TB, multi-drug resistant TB, extensively drug-resistant TB as well as totally drug-resistant TB have further aggravated the mortality and spread of this disease. Thus, there is an urgent need to develop novel anti-TB agents against both drug-susceptible and drug-resistant TB. The wide spectrum of biological activities and successful utilization of pyrazole-containing drugs in clinic have inspired more and more attention towards this kind of heterocycles. Numerous of pyrazole-containing derivatives have been synthesized for searching new anti-TB agents, and some of them showed promising potency and may have novel mechanism of action. This review aims to outline the recent achievements in pyrazole-containing derivatives as anti-TB agents and their structure-activity relationship.
Collapse
Affiliation(s)
- Zhi Xu
- Key Laboratory of Hubei Province for Coal Conversion and New Carbon Materials, Wuhan University of Science and Technology, Hubei, PR China
| | - Chuan Gao
- WuXi AppTec (Wuhan), Hubei, PR China
| | | | - Xu-Feng Song
- Beijing University of Technology, Beijing, PR China
| | | | - Zao-Sheng Lv
- Key Laboratory of Hubei Province for Coal Conversion and New Carbon Materials, Wuhan University of Science and Technology, Hubei, PR China.
| |
Collapse
|